Adeno-associated virus (AAV) platform development requires integrated strategies combining upstream process optimization, downstream purification, analytical method validation, and regulatory compliance. Our experience scaling multiple AAV serotypes (AAV1, AAV2, AAV5, AAV6, AAV9) demonstrates successful platform approaches.

Upstream manufacturing typically utilizes triple transfection of HEK293 cells with rep, cap, and transgene plasmids. Process optimization focuses on plasmid ratios, transfection timing, and culture duration. Optimized conditions achieve titers of 10¹³-10¹⁴ vg/ml supporting clinical manufacturing.

Downstream processing includes harvest, clarification, and purification. Cesium chloride gradient centrifugation represents gold standard for purification. Affinity chromatography and tangential flow filtration offer scalable alternatives. Integrated purification strategies achieve high purity and recovery.

Analytical method validation includes titer quantification (qPCR, ELISA), vector quality (capsid integrity assessment), empty particle quantification, and contamination testing. Each method requires validation demonstrating accuracy, precision, and specificity.

Formulation development optimizes product stability and storage conditions. Excipient screening identifies components enhancing stability. Stability studies at multiple temperatures establish shelf-life and storage requirements.

Regulatory compliance includes IND-enabling studies, CMC documentation, and ongoing GMP manufacturing. Quality control testing ensures product consistency and safety. Manufacturing scale-up supports clinical trial supply and commercial distribution.

Clinical applications include inherited retinal dystrophy, hemophilia, and spinal muscular atrophy. Successful clinical development demonstrates manufacturing platform robustness and regulatory acceptance.